27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a press release issued by Globe Newswire, Cesca Therapeutics Inc (NASDAQ: KOOL) announced approval for Medicare coverage for its CLIRST III study. This positive news has caused Cesca’s stock to open 21 percent higher than its closing price on Tuesday.
Cesca CEO Robin Stracey said, “We are very pleased with the CMS's decision to approve our potentially life changing, pivotal clinical study in critical limb ischemia ("CLI") for Medicare reimbursement...Medicare reimbursement will further the Company's efforts to find an effective treatment for CLI, the most severe form of peripheral arterial disease…”
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
What The Funding Means
The Medicare funding will allow the company to conduct their clinical trial at a lower cost than previously anticipated. There is a significant unmet demand for CLI treatment, with over 200,000 amputations for chronic foot and leg ulcers occurring each year. Cesca management hopes that the clinical trials will be successful and they can put the treatment to market and reduce these number of amputations.
Cesca Therapeutics was recently seen trading at $0.394, up 9.45 percent.
Image Credit: Public Domain27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.